VSV Vector Antigen Combinations for Tumor Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as surgery, chemotherapy, and radiation therapy, often have limitations in effectively targeting and reducing established tumors, especially in cases like melanoma and gliomas, which require more specific and effective antigen-based therapies.
Innovation Solution
The use of combinations of antigens, such as N-RAS, TYRP1, CYT-C, HIF-2α, SOX-10, and C-MYC, expressed via VSV vectors, administered to mammals to target and reduce cancer cells, potentially combined with immune checkpoint inhibitors like anti-PD-1 antibodies, to enhance treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combinations of multiple antigens are used to treat cancer, then treatment efficacy is improved, but device complexity increases
Solution Approach 1:
The patent combines multiple antigen-encoding nucleic acid molecules into a single composition that can be delivered together, merging the function of multiple separate treatments into one unified therapeutic approach while maintaining the benefits of antigen combination
Solution Approach 2:
The composition is designed to encode multiple different antigens (HIF-2α, SOX-10, C-MYC, TYRP-1) that can target various aspects of cancer biology, making a single composition capable of performing multiple therapeutic functions simultaneously
2Reliability
If VSV vectors expressing multiple antigens are administered, then immune response is enhanced, but manufacturing complexity increases
Solution Approach 1:
Multiple antigen-encoding nucleic acid molecules are combined into a single VSV vector composition, allowing simultaneous delivery of multiple antigens through one vector system rather than requiring separate vectors for each antigen
Data Source
AI summary
This document provides methods and materials for treating cancer. For example, methods and materials for identifying antigens and combinations of antigens that can be used to treat cancer as well as combinations of antigens having the ability to reduce established tumors (e.g., gliomas) within a mammal (e.g., a human) are provided.